Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Deferred Taxes (2017 - 2023)

Historic Deferred Taxes for BeOne Medicines (BEIGF) over the last 7 years, with Q4 2023 value amounting to -$46000.0.

  • BeOne Medicines' Deferred Taxes fell 10273.97% to -$46000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $689000.0, marking a year-over-year decrease of 6653.72%. This contributed to the annual value of $26.0 million for FY2024, which is 367111.76% up from last year.
  • As of Q4 2023, BeOne Medicines' Deferred Taxes stood at -$46000.0, which was down 10273.97% from $750000.0 recorded in Q3 2023.
  • BeOne Medicines' 5-year Deferred Taxes high stood at $14.8 million for Q3 2021, and its period low was -$12.3 million during Q1 2021.
  • For the 5-year period, BeOne Medicines' Deferred Taxes averaged around -$142300.0, with its median value being -$48500.0 (2023).
  • Per our database at Business Quant, BeOne Medicines' Deferred Taxes tumbled by 584708.74% in 2021 and then skyrocketed by 94166.67% in 2022.
  • Over the past 5 years, BeOne Medicines' Deferred Taxes (Quarter) stood at $4.1 million in 2019, then soared by 119.97% to $9.0 million in 2020, then plummeted by 89.99% to $903000.0 in 2021, then skyrocketed by 85.94% to $1.7 million in 2022, then crashed by 102.74% to -$46000.0 in 2023.
  • Its Deferred Taxes stands at -$46000.0 for Q4 2023, versus $750000.0 for Q3 2023 and -$51000.0 for Q2 2023.